ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Trial of Adalimumab in Progressive Sarcoidosis

ClinicalTrials.gov ID: NCT00311246

Public ClinicalTrials.gov record NCT00311246. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective Open-Label Trial of Adalimumab in Progressive Sarcoidosis

Study identification

NCT ID
NCT00311246
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of Chicago
Other
Enrollment
11 participants

Conditions and interventions

Conditions

Interventions

  • Adalimumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2006
Primary completion
Apr 30, 2008
Completion
Aug 31, 2008
Last update posted
Aug 24, 2020

2006 – 2008

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
The University of Chicago Chicago Illinois 60637

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00311246, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 24, 2020 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00311246 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →